RB1 and breast carcinoma: Downregulation of the Rb pathway in ER+ breast cancer seems also to be associated with a more aggressive tumour growth and rapid recurrence on endocrine therapy (Cadoo et al, 2014; Witkiewicz and Knudsen, 2014).